There are no well controlled studies with Haldol (haloperidol) in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of Haldol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to Haldol, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus.
PGxOne™ Plus Pharmacogenomics Test PGxOne™ Plus is a pharmacogenomics test that predicts how patients will respond to drug therapy based on their individual genetic makeup. Differences between individuals can affect drug absorption, metabolism, or activity. Therefore, while one treatment regimen may work well for one individual, the same regimen may cause adverse effects for other individuals. 1, 2 PGxOne™ Plus comprehensively screens 50 well-established pharmacogenomic genes in a single, cost-effective test that provides medically actionable and clinically relevant data, thus allowing physicians to make effective treatment decisions. Expanding beyond pharmacogenomics, PGxOne™ Plus reports potential adverse interactions of the patient’s current medications.
back to top
Zegerid (omeprazole/sodium bicarbonate)
Zelnorm (tegaserod maleate)
Ziagen (abacavir sulfate)
Zohydro (hydrocodone bitartrate extended-release capsules)
Zolpimist (zolidem tartrate)
Zometa (zoledronic acid)
Zyban (bupropion hydrochloride)